Thirty-eight years ago, I was initiated into the oldest and one of the largest Black fraternities in the world: Alpha Phi Alpha Fraternity, Inc. It was one of the happiest days of my life. In ...

Bayer (XTRA:BAYN) has received preliminary US court approval for a multibillion-dollar class action settlement tied to Monsanto's Roundup weedkiller. The proposed agreement is intended to address tens ...

More than 70% of patients with biochemically recurrent prostate cancer remained metastasis-free 5 years after PSMA PET/CT-guided salvage radiation therapy. Whole-pelvis radiation significantly ...

Johnson & Johnson (NYSE:JNJ) received FDA Fast Track designation for nipocalimab as a potential treatment for systemic lupus ...

New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to ...

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) stock gained 3.9% in premarket trading Tuesday following positive clinical data from its Phase 1/2 study of MRT-2359 in combination with enzalutamide for ...

Pooled trials show Pluvicto improves progression-free survival in advanced prostate cancer, without increasing serious adverse events. An examination of data from more than 2500 patients with advanced ...

King Faisal Specialist Hospital and Research Centre (KFSH) in Riyadh has successfully introduced a pioneering high-intensity focused ultrasound (HIFU) treatment for prostate cancer for the first time ...

Bayer has reported a major development within its pharmaceutical pipeline, with new clinical trial data indicating a significant improvement in survival rates for patients with advanced prostate ...

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3 Data highlight the potential of this first-in-class next-generation ...

In February 2026, Bayer filed a lawsuit in U.S. federal court accusing Johnson & Johnson and Janssen Biotech of falsely promoting the superiority of prostate cancer drug ERLEADA over Bayer’s NUBEQA ...